← All trials
NCT06220162
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2024
- Primary completion
- Dec 1, 2026
- Completion date
- Dec 1, 2026
- First posted
- Jan 23, 2024
- Last posted
- Feb 26, 2024
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Soochow UniversityLead sponsor
- Nanjing Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- The Second People's Hospital of Huai'anCollaborator
- Nantong UniversityCollaborator
- Bengbu Medical CollegeCollaborator
- Soochow UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.